Current progress in dengue vaccines

Shu Wen Wan, Chiou Feng Lin, Shuying Wang, Yu Hung Chen, Trai Ming Yeh, Hsiao Sheng Liu, Robert Anderson, Yee Shin Lin

研究成果: Review article

48 引文 (Scopus)

摘要

Dengue is one of the most important emerging vector-borne viral diseases. There are four serotypes of dengue viruses (DENV), each of which is capable of causing self-limited dengue fever (DF) or even life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The major clinical manifestations of severe DENV disease are vascular leakage, thrombocytopenia, and hemorrhage, yet the detailed mechanisms are not fully resolved. Besides the direct effects of the virus, immunopathological aspects are also involved in the development of dengue symptoms. Although no licensed dengue vaccine is yet available, several vaccine candidates are under development, including live attenuated virus vaccines, live chimeric virus vaccines, inactivated virus vaccines, and live recombinant, DNA and subunit vaccines. The live attenuated virus vaccines and live chimeric virus vaccines are undergoing clinical evaluation. The other vaccine candidates have been evaluated in preclinical animal models or are being prepared for clinical trials. For the safety and efficacy of dengue vaccines, the immunopathogenic complications such as antibody-mediated enhancement and autoimmunity of dengue disease need to be considered.

原文English
文章編號37
期刊Journal of biomedical science
20
發行號1
DOIs
出版狀態Published - 2013 六月 17

指紋

Dengue Vaccines
Viruses
Severe Dengue
Attenuated Vaccines
Dengue
Vaccines
Dengue Virus
Virus Diseases
Inactivated Vaccines
Subunit Vaccines
DNA Vaccines
Autoimmunity
Thrombocytopenia
Blood Vessels
Animal Models
Clinical Trials
Hemorrhage
Safety
Animals
Antibodies

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Molecular Biology
  • Clinical Biochemistry
  • Cell Biology
  • Biochemistry, medical
  • Pharmacology (medical)

引用此文

Wan, Shu Wen ; Lin, Chiou Feng ; Wang, Shuying ; Chen, Yu Hung ; Yeh, Trai Ming ; Liu, Hsiao Sheng ; Anderson, Robert ; Lin, Yee Shin. / Current progress in dengue vaccines. 於: Journal of biomedical science. 2013 ; 卷 20, 編號 1.
@article{67cb4dbd93a840189c8fd166a9c07067,
title = "Current progress in dengue vaccines",
abstract = "Dengue is one of the most important emerging vector-borne viral diseases. There are four serotypes of dengue viruses (DENV), each of which is capable of causing self-limited dengue fever (DF) or even life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The major clinical manifestations of severe DENV disease are vascular leakage, thrombocytopenia, and hemorrhage, yet the detailed mechanisms are not fully resolved. Besides the direct effects of the virus, immunopathological aspects are also involved in the development of dengue symptoms. Although no licensed dengue vaccine is yet available, several vaccine candidates are under development, including live attenuated virus vaccines, live chimeric virus vaccines, inactivated virus vaccines, and live recombinant, DNA and subunit vaccines. The live attenuated virus vaccines and live chimeric virus vaccines are undergoing clinical evaluation. The other vaccine candidates have been evaluated in preclinical animal models or are being prepared for clinical trials. For the safety and efficacy of dengue vaccines, the immunopathogenic complications such as antibody-mediated enhancement and autoimmunity of dengue disease need to be considered.",
author = "Wan, {Shu Wen} and Lin, {Chiou Feng} and Shuying Wang and Chen, {Yu Hung} and Yeh, {Trai Ming} and Liu, {Hsiao Sheng} and Robert Anderson and Lin, {Yee Shin}",
year = "2013",
month = "6",
day = "17",
doi = "10.1186/1423-0127-20-37",
language = "English",
volume = "20",
journal = "Journal of Biomedical Science",
issn = "1021-7770",
publisher = "BioMed Central",
number = "1",

}

Current progress in dengue vaccines. / Wan, Shu Wen; Lin, Chiou Feng; Wang, Shuying; Chen, Yu Hung; Yeh, Trai Ming; Liu, Hsiao Sheng; Anderson, Robert; Lin, Yee Shin.

於: Journal of biomedical science, 卷 20, 編號 1, 37, 17.06.2013.

研究成果: Review article

TY - JOUR

T1 - Current progress in dengue vaccines

AU - Wan, Shu Wen

AU - Lin, Chiou Feng

AU - Wang, Shuying

AU - Chen, Yu Hung

AU - Yeh, Trai Ming

AU - Liu, Hsiao Sheng

AU - Anderson, Robert

AU - Lin, Yee Shin

PY - 2013/6/17

Y1 - 2013/6/17

N2 - Dengue is one of the most important emerging vector-borne viral diseases. There are four serotypes of dengue viruses (DENV), each of which is capable of causing self-limited dengue fever (DF) or even life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The major clinical manifestations of severe DENV disease are vascular leakage, thrombocytopenia, and hemorrhage, yet the detailed mechanisms are not fully resolved. Besides the direct effects of the virus, immunopathological aspects are also involved in the development of dengue symptoms. Although no licensed dengue vaccine is yet available, several vaccine candidates are under development, including live attenuated virus vaccines, live chimeric virus vaccines, inactivated virus vaccines, and live recombinant, DNA and subunit vaccines. The live attenuated virus vaccines and live chimeric virus vaccines are undergoing clinical evaluation. The other vaccine candidates have been evaluated in preclinical animal models or are being prepared for clinical trials. For the safety and efficacy of dengue vaccines, the immunopathogenic complications such as antibody-mediated enhancement and autoimmunity of dengue disease need to be considered.

AB - Dengue is one of the most important emerging vector-borne viral diseases. There are four serotypes of dengue viruses (DENV), each of which is capable of causing self-limited dengue fever (DF) or even life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The major clinical manifestations of severe DENV disease are vascular leakage, thrombocytopenia, and hemorrhage, yet the detailed mechanisms are not fully resolved. Besides the direct effects of the virus, immunopathological aspects are also involved in the development of dengue symptoms. Although no licensed dengue vaccine is yet available, several vaccine candidates are under development, including live attenuated virus vaccines, live chimeric virus vaccines, inactivated virus vaccines, and live recombinant, DNA and subunit vaccines. The live attenuated virus vaccines and live chimeric virus vaccines are undergoing clinical evaluation. The other vaccine candidates have been evaluated in preclinical animal models or are being prepared for clinical trials. For the safety and efficacy of dengue vaccines, the immunopathogenic complications such as antibody-mediated enhancement and autoimmunity of dengue disease need to be considered.

UR - http://www.scopus.com/inward/record.url?scp=84878818110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878818110&partnerID=8YFLogxK

U2 - 10.1186/1423-0127-20-37

DO - 10.1186/1423-0127-20-37

M3 - Review article

C2 - 23758699

AN - SCOPUS:84878818110

VL - 20

JO - Journal of Biomedical Science

JF - Journal of Biomedical Science

SN - 1021-7770

IS - 1

M1 - 37

ER -